E7090

Phase 2Small molecule

Eisai

E7090 is one of 72 small molecule programs targeting Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

CholangiocarcinomaActive, not recruiting

Breast CancerPhase 1

Active, not recruiting

CholangiocarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Prolia

Amgen

Preclinical

14 2

DATROWAY

Daiichi Sankyo

Preclinical

4 3

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 5

E7090

Eisai

Phase 2

1 6

Acupan

YYonsei University

Preclinical

1 7

Nubain

AAultman Health Foundation

Preclinical

1 8

Paracetamol

GSK

Preclinical

1 9

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 10

Dextromethorphan Hydrobromide

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

Breast Cancer

NCT04572295

Q1 2028

Phase 2Recruiting

Trial

NCT04962867

Clinical

Trials by Indication[1]

Trial1 trial

NCCH2006/MK010 Trial (FORTUNE Trial)

Recruiting·NNational Cancer Center, Japan·Phase 2·NCT04962867·75 enrolled

Drug Interactions1 trial

A Study to Assess the Effect of Food Intake and Drug-drug Interactions of E7090 When Co-administered With Rabeprazole or Rifampin in Healthy Participants

Completed· Eisai logo

Eisai·Phase 1·NCT04565574·42 enrolled

Breast Cancer1 trial

A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer

Active, not recruiting· Eisai logo

Eisai·Phase 1·NCT04572295·51 enrolled

Cholangiocarcinoma1 trial

A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion

Completed· Eisai logo

Eisai·Phase 2·NCT04238715·63 enrolled

Solid Tumor1 trial

Phase 1 Study of E7090 in Subjects With Solid Tumor

Completed· Eisai logo

Eisai·Phase 1·NCT02275910·40 enrolled

1 more indication

Metabolism1 trial

A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants

Completed· Eisai logo

Eisai·Phase 1·NCT04493255·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for E7090. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — E7090 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for E7090. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eisai company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Eisai

E7090

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q1 2028

Trials by Indication[1]

Trial1 trial

Drug Interactions1 trial

Breast Cancer1 trial

Cholangiocarcinoma1 trial

Solid Tumor1 trial

Metabolism1 trial

References

Drug Info

Quick Facts

Related News